As reported previously, Baird analyst Eric Coldwell upgraded Diplomat Pharmacy to Neutral from Underperform. The analyst said he is now less cautious than he was following the Q3 report. He met with management and came away raising his forecasts for 2019. Coldwell raised his price target to $15 from $10 on Diplomat Pharmacy shares.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.